Home > News > BioAscent and Selcia Collaboration Enhances Compound Cloud Online Collection with Unique Fragment Library
Industry Updates New Products Supplier News Upcoming Events business web

BioAscent and Selcia Collaboration Enhances Compound Cloud Online Collection with Unique Fragment Library

Hits:2196   Date: 8/3/2016
Selcia’s compound library for early stage drug discovery can now be ordered in a ready-to-use format through Compound Cloud
NEWHOUSE, UK (2 August 2016): BioAscent Discovery (www.bioascent.com) and Selcia have entered into an agreement to make Selcia’s unique compound fragment library available to researchers through BioAscent’s new online Compound Cloud service. The new agreement adds to the 125,000+ compounds available through Compound Cloud and stored at BioAscent’s state-of-the-art compound management and logistics facility. Scientists can now benefit from immediate access to Selcia’s 1366 fragment collection, which has been designed in collaboration with Cambridge MedChem Consulting. The collection contains a structurally-diverse range of compounds with little overlap with other commercially-available libraries consisting of both commercial and non-commercial custom synthesised fragments. All have been put through a stringent quality control process to ensure chemical attractiveness and stability. Customers can order ready-to-use, single-use sets for rapid despatch through Compound Cloud.

Compound Cloud promises to significantly enhance early-stage drug discovery, by enabling easy online selection and ordering of a diverse collection of IP-free, high quality chemicals for screening, including an increasing number of third party collections. It applies the cloud-computing concept to early stage drug discovery by enabling scientists to remotely pick and choose specific compounds of interest from BioAscent’s storage facility and have them quickly prepared and delivered for immediate use. By removing the need for organisations to expend resources in developing or acquiring compound collections, compound screening through Compound Cloud becomes highly cost- and time-efficient.
For more information, please visit the Compound Cloud website at www.compoundcloud.com.
BioAscent Discovery Ltd.
Founded in 2013, BioAscent is the rejuvenated former Merck Sharpe and Dohme (MSD) automated compound management and logistics facility, based within the BioCity Scotland site at Newhouse, Scotland, UK. The company consists of a state-of-the-art facility run by a range of highly skilled management, scientists, and technicians with extensive experience in managing specialist compound libraries. It offers the safe and secure storage of customer compound collections, in addition to formatting and worldwide logistics. BioAscent was selected as the Centre of Excellence for the compound management activities of the Innovative Medicines Initiative (IMI)-funded European Lead Factory, providing secure storage and logistics of the 500,000 sample collection to all partners. BioAscent is also a broker supplying access to specialized sample collections to organisations worldwide.